Epigenomics Crosses Finishing Line Of Long US Reg Journey For Epi proColon
This article was originally published in Clinica
Executive Summary
Epigenomics has finally gained US FDA approval for its Epi proColon noninvasive colorectal cancer screening test, ending what has been a long, obstacle-filled journey for the German-US molecular diagnostics company.